Severe congenital neutropenia (SCN) is a disorder of myelopoiesis characterized by severe neutropenia or absence of blood neutrophils secondary to a maturational arrest at the level of promyelocytes. We examined peripheral blood mononuclear cells (PBMC) of SCN patients who demonstrated normalization of their blood neutrophil counts in a phase II clinical study with recombinant human granulocyte colonystimulating factor (rhG-CSF). When stimulated in vitro with bacterial lipopolysaccharides (LPS), PBMC of those SCN EVERE CONGENITAL neutropenia (SCN), or Kost-S mann syndrome, first described by Kostmann in 1956,' is a disorder of myelopoiesis characterized by severe neutropenia secondary to a maturational arrest on the level of promyelocyte~.~~~ The etiology of SCN is unknown. Levels of circulating neutrophils in children with SCN have been restored to normal by administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF),45 suggesting a defect in endogenous G-CSF production. To investigate whether cells from children with SCN are capable of producing G-CSF, we stimulated peripheral blood mononuclear cells (PBMC) from these children with bacterial lipopolysaccharide (LPS) in vitro. In this study, we showed that PBMC from patients with SCN can be stimulated to synthesize and secrete biologically active G-CSF in vitro.
1 m m o m L-glutamine, 20 mmol/L HEPES, and antibiotics) and 10% fetal calf serum (FCS, GIBCO, Eggenstein, Germany). Cell concentration was adjusted to lo6 monocytes per milliliter. In this article, the term PBMC is used for PBMC adjusted for monocytes. PBMC were stimulated with sonicated LPS from Escherichia coli, serotype Olll:B4 (Sigma, Deisenhofen, Germany) at 100 ng/mL for 48 hours. Previous time and concentration kinetic experiments with PBMC from healthy volunteers have shown that stimulation with LPS for 48 hours results in maximum G-CSF content in the supernatants of PBMC.
The murine MoAb TM-8260 was produced by a protocol described previously.6 After BALBIc X C57BI6 F,-mice were immunized, their spleens were removed, mashed, and fused with murine myeloma cells (P3-NSI-Ag4-1) with a polyethylene glycol solution (PEG 4000, Merck, Darmstadt, Germany). Screening of the supernatants of the hybridomas was performed by an anti-G-CSF-specific enzyme-linked immunosorbent assay (ELISA). An anti-G-CSF-specific clone TM-8260 (IgG1 subclass) was detected and subcloned. TM-8260 ascites was produced by injecting -5 x lo6 hybridoma cells into the peritoneal cavity of female BALBIc mice primed with 0.5 mL Pristane (2, 6, 10, 14-tetramethylpentadecane; Sigma). After puncture, ascites was centrifuged, 0.02% NaN, was added and stored in aliquots at Total cellular RNA was isolated by lysis in 4 momguanidine isothiocyanate and centrifugation through 5.7 mol/L cesium chloride as described previously.' Fifteen micrograms RNA per lane was fractionated on 1.2% agarose gels containing 0.7 m o m formaldehyde, transferred to nitrocellulose filters (Schleicher and Schiill, Dassel, Germany) by capillary suction overnight, and fixed by baking for 2 hours at 80°C. A human G-CSF cDNA (provided by Dr L. Souza, Amgen, Thousand Oaks, CA) was "P-labeled using the hexanucleotide random prime method! Hybridization was performed for 16 hours at 42°C in 4 x SSC, 50% formamide and 1 x Denhardt's solution. Subsequently, filters were washed twice for 30 minutes at 65°C in 0.1 X SSC and 0.1% sodium dodecyl sulfate (SDS) and autoradiographed at Supernatants of stimulated PBMC were concentrated by loading 5-mL aliquots on Sep-Pack C,,-columns (Waters, Eschborn, Germany). Columns were washed sequentially with 2 mL buffer A (0.1 m o m ammonium acetate buffer, pH 4.0), 1 mL buffer A containing 25% 2-propanol, and 1 mL buffer A containing 50% propanol. The last 0.75 mL eluting from the column was collected and dried under vaccum overnight at -60°C. The dried residue was dissolved in 0.1 mL sample buffer (0.06 m o m Tris-HC1, pH 6.8; 2% SDS; 10% glycerol; 5% 2-mercaptoethanol). Two microliters was loaded on 10% to 15% SDS polyacrylamide gradient gel and run on a Phast System separation unit (Pharmacia, Freiburg, Germany). After electrophoresis, proMonoclonal antibody (MoAb).
Northern blot analysis.
-80°C. Western blot analysis. The amount of G-CSF was calculated by comparing the intensity of the stained protein bands with the bands of standard dilutions of G-CSF by a video-densitometer (Biotec Fischer, Reisskirchen, Germany). The detection limit using this method was G-CSF 10 pg/mL culture supernatant.
The murine myeloid leukemia cell line NFS-60 (provided by W. Farrar, National Cancer Institute, Frederick, MD), was used to determine G-CSF levels in supematants of stimulated PBMC." Serial dilutions of supernatants and appropriate controls were incubated with NFS-60 cells (l@/mL) for 48 hours and 0.5 pCi of 'H-thymidine (Amersham-Buchler, Braunschweig, Germany) was added for the last 4 hours of culture. Cells were then lysed, and DNA was harvested on glass fiber strips. Incorporated radioactivity was measured in a liquid scintillation counter. Serial dilutions of rhG-CSF were used as standard, and the concentrations of the samples were calculated from the standard curve by probit analysis and shown in picograms per milliliter. Individual samples were also tested in the presence of a dilution of 1: 1, OOO of a neutralizing anti-G-CSF antiserum raised in rabbits or in the presence of preimmune rabbit serum.
NFS-60 proliferation assay.

RESULTS
PBMC from patients and healthy human volunteers were stimulated with bacterial LPS for 48 hours. Bacterial LPS is an adequate stimulus for human monocytes,12 the G-CSFproducing subpopulation in PBMC. If not indicated otherwise, LPS was used in a concentration of 100 ng/mL, because initial experiments showed maximum G-CSF secretion by PBMC of a SCN patient and an age-matched healthy control person at this dosage (Fig 1) . With use of LPS in concentrations of 1, 10, 100, and 1,000 ng/mL, the amount of G-CSF secreted by SCN PBMC was similar to that of PBMC from controls. However, monocytes from SCN patients also produced G-CSF without stimulation, whereas no G-CSF was detected in supernatants of control PBMC under the same conditions (Fig 1) . PBMC supematants were collected, concentrated, and analyzed by Western blot for the presence of G-CSF. Bands with an apparent molecular weight (mol wt) of 19,600 daltons could be detected (Fig 2) . As a control, rhG-CSF with a mol wt of 18,800 was used. In one patient (a 21-year-old man) and in one healthy volunteer, supernatants from stimulated PBMC were removed at 8, 18, 48, 72, and 96 hours, respectively, after addition of LPS. Maximum G-CSF content could be detected after 48 hours of stimulation [Fig 2; (patient 3 , O.K.) and data not shown]. Therefore, PBMC from patients were stimulated for 48 hours (Fig 2) . The amounts of G-CSF were measured by comparing the density of protein bands with G-CSF standards after the bands were scanned with a video-densitometer. Results are shown in Table 2 .
Total RNA was extracted from PBMC of one patient and one healthy volunteer 3 hours after stimulation with LPS. Northern blot analysis for the presence of G-CSF-specific messenger RNA showed hybridization signals at approximately 1.8 kd (Fig 3) . No difference in size of the mRNA coding for G-CSF was noted between patient and control.
Supernatants of LPS-stimulated PBMC were also investigated for G-CSF activity with a proliferation assay with murine NFS-60 leukemia cells as a target. PBMC adjusted to lo6 monocytes per milliliter were stimulated with LPS for 48 hours. To test for G-CSF activity, NFS-60 cells were incubated with serial dilutions of PBMC supernatants. Significant proliferation was induced by supernatants of all patients tested (Table 2 ). In the presence of anti-G-CSF antiserum, this bioactivity was neutralized, whereas preimmune serum had no effect in this assay system. Patients with SCN have been shown to respond to administered rhG-CSF with a dose-dependent increase in blood neutrophil counts to near-normal levels." This suggests a defect in production of G-CSF, other hematopoietic differential factors, or both in these patients. In the present study, however, we showed that PBMC from patients with SCN are capable of producing sufficient amounts of biologically active G-CSF after stimulation with bacterial LPS in vitro. Furthermore, the PBMC of SCN patients appear to be preactivated in vivo because they also produce G-CSF without in vitro stimulation. This preactivation of PBMC during rhG-CSF treatment could be explained by indirect stimulation of these cells by G-CSF by other cytokines. Although the capacity of monocytes to produce G-CSF varied significantly under these in vitro conditions, we found biologically active protein in all samples. The differ- For personal use only. on October 30, 2017. by guest www.bloodjournal.org From ences between the bioassay and Western blot analysis most likely were the result of the multiple-step sample preparation before the Western blot analysis and densitometry. The bioassay used is specific for G-CSF, as was evident in sample 3 and a control. Thus, the defect responsible for SCN does not appear to be either a general inability to synthesize and or secrete G-CSF or production of biologically inactive G-CSF species by monocytes, although a reduced specific activity cannot be excluded completely. G-CSF production of isolated PBMC in vitro does not necessarily reflect regulation of G-CSF production in vivo. On the other hand, we were able to detect biologically active G-CSF in the serum of SCN patients." Besides monocytes,'* various normal tissues such as fibroblast^'^ and endothelial cells14 from healthy volunteers have been shown to secrete G-CSF in vitro after stimulation with interleukin 1 (IL-1) and/or tumor necrosis factor-a (TNF-a). In another study, bone marrow fibroblasts from patients with SCN were shown to be capable of producing G-CSF in ~i t r 0 . I~ A more likely explanation of the defect responsible for SCN is that precursors from patients with SCN require G-CSF dosages substantially higher than those from healthy individuals to differentiate to normal neutrophils, which suggests an impaired affinity of the G-CSF receptor to G-CSF, low receptor numbers, or defective intracellular signal transduction. This explanation is supported by results of an ongoing clinical trial with rhG-CSF: Dosages 2 10 pgkg per day, enough to increase the absolute neutrophil count (ANC) in other patients to more than 30,000/pL,16 lead only to neutrophil counts of approximately l,OOO/pL in most patients: Neutropenia in itself does not appear to trigger endogenous G-CSF levels comparable to the pharmacologic levels reached in clinical trials. SCN is a rare disease that might also be of heterogeneous etiology. Data suggest that a defect on the receptor that was recently cloned," intracellular transduction level, or both are more likely to be part of the underlying pathomechanism than a general disability to produce biologically active G-CSF. Further studies will be necessary to elucidate the molecular defects involved in SCN.
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